Keywords: Pfizer, Lyrica, Post-marketing studies, Males reproductive function, Genealized anxiety disorder

Pfizer's Lyrica positive in two post-marketing studies

Article | 23 July 2012

Print This

Top-line results for global drugs behemoth Pfizer’s already marketed diabetic nerve pain and post-herpetic neuralgia drug Lyrica (pregabalin) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in